MedTrace Logo

Evaluation of CMV/EBV-CMI in Haploid HSCT

NCT06554197 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-08-15

No results posted yet for this study

Summary

The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .

Conditions

  • Hematopoietic Stem Cell Transplantation
  • Cytomegalovirus Infections
  • Epstein-Barr Virus Infections

Interventions

DIAGNOSTIC_TEST

CMV/EBV-CMI

The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90 days, 120 days, 180 days after transplantation.

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-13
Primary Completion
2025-07-31
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06554197 on ClinicalTrials.gov